News Image

NASDAQ:EXEL, a growth stock which is not overvalued.

By Mill Chart

Last update: Nov 29, 2023

Our stock screener has singled out EXELIXIS INC (NASDAQ:EXEL) as an attractive growth opportunity. NASDAQ:EXEL is demonstrating remarkable growth potential while maintaining strong financial indicators, making it a reasonably priced option. We'll explore this further.

Deciphering NASDAQ:EXEL's Growth Rating

ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:EXEL was assigned a score of 7 for growth:

  • The Revenue has grown by 8.31% in the past year. This is quite good.
  • EXEL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.91% yearly.
  • Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 33.60% on average per year.
  • EXEL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.53% yearly.
  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

A Closer Look at Valuation for NASDAQ:EXEL

ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:EXEL scores a 6 out of 10:

  • 93.98% of the companies in the same industry are more expensive than EXEL, based on the Price/Earnings ratio.
  • EXEL's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 96.32% of the companies in the same industry.
  • 93.65% of the companies in the same industry are more expensive than EXEL, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.82% of the companies listed in the same industry.
  • The excellent profitability rating of EXEL may justify a higher PE ratio.
  • A more expensive valuation may be justified as EXEL's earnings are expected to grow with 28.74% in the coming years.

ChartMill's Evaluation of Health

ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:EXEL scores a 7 out of 10:

  • An Altman-Z score of 7.40 indicates that EXEL is not in any danger for bankruptcy at the moment.
  • EXEL has a Altman-Z score of 7.40. This is amongst the best in the industry. EXEL outperforms 86.29% of its industry peers.
  • EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • EXEL has a Current Ratio of 3.83. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
  • EXEL has a Quick Ratio of 3.76. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.

How do we evaluate the Profitability for NASDAQ:EXEL?

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:EXEL has earned a 8 out of 10:

  • With an excellent Return On Assets value of 3.09%, EXEL belongs to the best of the industry, outperforming 95.32% of the companies in the same industry.
  • The Return On Equity of EXEL (3.92%) is better than 94.82% of its industry peers.
  • EXEL's Return On Invested Capital of 1.23% is amongst the best of the industry. EXEL outperforms 94.31% of its industry peers.
  • The 3 year average ROIC (6.67%) for EXEL is well above the current ROIC(1.23%). The reason for the recent decline needs to be investigated.
  • EXEL has a better Profit Margin (5.18%) than 95.65% of its industry peers.
  • EXEL has a Operating Margin of 2.31%. This is amongst the best in the industry. EXEL outperforms 94.31% of its industry peers.
  • EXEL has a better Gross Margin (96.24%) than 95.82% of its industry peers.

Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.

For an up to date full fundamental analysis you can check the fundamental report of EXEL

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

EXELIXIS INC

NASDAQ:EXEL (2/23/2024, 11:42:03 AM)

21.515

+0.8 (+3.89%)

EXEL News

News Image2 hours ago - Market News VideoFriday 2/23 Insider Buying Report: EXEL, HPP
News Image4 days ago - The Motley Fool2 Stocks Under $30 to Buy and Hold

You don't need to be a millionaire to get started. Investing on a budget can work, too.

News Image9 days ago - FinancialNewsMediaAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

News Image9 days ago - FN Media Group LLCAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
News Image10 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in February 2024

The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes.

News Image10 days ago - ChartmillIn a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

News Image13 days ago - The Motley Fool4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains.

News Image16 days ago - Market News VideoExelixis Larger Than S&P 500 Component Whirlpool
News Image16 days ago - Market News VideoExelixis Becomes Oversold (EXEL)
News Image16 days ago - Market News VideoEXEL Crosses Below Key Moving Average Level
News Image17 days ago - The Motley FoolExelixis (EXEL) Q4 2023 Earnings Call Transcript

EXEL earnings call for the period ending December 31, 2023.

News Image17 days ago - Seeking AlphaExelixis Non-GAAP EPS of $0.33 beats by $0.02, revenue of $480M beats by $2.08M (NASDAQ:EXEL)

Exelixis beats expectations with Q4 financial results: Non-GAAP EPS of $0.33, revenue of $480M (+13.2% Y/Y), and 2024 guidance of $1.825B-$1.925B.

EXEL Links
Follow us for more